AI assistant
Sending…
Spero Therapeutics, Inc. — Director's Dealing 2018
Jan 5, 2018
34087_dirs_2018-01-05_906e2a4d-3f9c-4654-9fd2-68da715c1394.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Spero Therapeutics, Inc. (SPRO)
CIK: 0001701108
Period of Report: 2018-01-04
Reporting Person: Melnick David A. (Chief Medical Officer)
More from Spero Therapeutics, Inc.
Regulatory Filings
2026
May 13
Annual Report
2026
Apr 27
Proxy Solicitation & Information Statement
2026
Apr 27
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 4
Board/Management Information
2026
Jan 30
Regulatory Filings
2025
Dec 19
Regulatory Filings
2025
Nov 13